Literature DB >> 34515805

Long-term Outcome of Chilblains Associated with SARS-CoV-2.

Florence Poizeau, Sébastien Barbarot, Yannick Le Corre, Emilie Brenaut, Mahtab Samimi, Hélène Aubert, Alexis Toubel, Alain Dupuy1.   

Abstract

Numerous cases of chilblains have been observed in the course if the COVID-19 pandemic. The aims of this study were to provide comprehensive follow-up data for patients reporting chilblains, and to determine the risk factors for incomplete recovery. Patients referred to 5 hospitals in France between March and May 2020 for chilblains were surveyed on December 2020. A teleconsultation was offered. Among 82 patients reporting chilblains, 27 (33%) reported complete recovery, 33 (40%) had recurrences of chilblains after their hands and feet had returned to normal, and 22 (27%) developed persistent acral manifestations, mostly acrocyanosis, with or without further recurrences of chilblains. Most recurrences of chilblains occurred during the following autumn and winter. A past history of chilblains was not associated with recurrences or persistent acral manifestations. Women had a significantly higher risk of developing recurrences or persistent acral manifestations (odds ratio 1.30; 95% confidence interval 1.06-1.59). In conclusion, two-thirds of patients reporting chilblains at the start of the COVID-19 pandemic experienced persistent or recurrent acral manifestations after a 10-month follow-up.

Entities:  

Mesh:

Year:  2021        PMID: 34515805      PMCID: PMC9472087          DOI: 10.2340/00015555-3930

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  34 in total

Review 1.  The Overlap between Genetic Susceptibility to COVID-19 and Skin Diseases.

Authors:  Navid Jabalameli; Fateme Rajabi; Alireza Firooz; Nima Rezaei
Journal:  Immunol Invest       Date:  2021-01-26       Impact factor: 3.657

2.  Long COVID in the Faroe Islands: A Longitudinal Study Among Nonhospitalized Patients.

Authors:  Maria Skaalum Petersen; Marnar Fríðheim Kristiansen; Katrin Dahl Hanusson; Marjun Eivindardóttir Danielsen; Bjarni Á Steig; Shahin Gaini; Marin Strøm; Pál Weihe
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

3.  Frequency of relapse and persistent cutaneous symptoms after a first episode of chilblain-like lesion during the COVID-19 pandemic.

Authors:  P Moghadam; L Frumholtz; L Jaume; A De Masson; M Jachiet; E Begon; L Sulimovic; A Petit; H Bachelez; M Bagot; J-D Bouaziz; C Cassius
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-06-19       Impact factor: 9.228

4.  When interferon tiptoes through COVID-19: Pernio-like lesions and their prognostic implications during SARS-CoV-2 infection.

Authors:  William Damsky; Danielle Peterson; Brett King
Journal:  J Am Acad Dermatol       Date:  2020-06-19       Impact factor: 11.527

5.  Type I Interferon Signature in Chilblain-Like Lesions Associated with the COVID-19 Pandemic.

Authors:  Roland Aschoff; Nick Zimmermann; Stefan Beissert; Claudia Günther
Journal:  Dermatopathology (Basel)       Date:  2020-12-04

6.  Chilblains during lockdown are associated with household exposure to SARS-CoV-2: a multicentre case-control study.

Authors:  Florence Poizeau; Emmanuel Oger; Sébastien Barbarot; Yannick Le Corre; Mahtab Samimi; Emilie Brenaut; Hélène Aubert; Estel Chambrelan; Catherine Droitcourt; Valérie Gissot; Christopher Heslan; Claire Laurent; Ludovic Martin; Laurent Misery; Pierre Tattevin; Alexis Toubel; Vincent Thibault; Alain Dupuy
Journal:  Clin Microbiol Infect       Date:  2021-10-04       Impact factor: 8.067

7.  Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing.

Authors:  L Le Cleach; L Dousset; H Assier; S Fourati; S Barbarot; C Boulard; C Bourseau Quetier; L Cambon; C Cazanave; A Colin; E Kostrzewa; C Lesort; A Levy Roy; F Lombart; J Marco-Bonnet; J-B Monfort; M Samimi; M Tardieu; P Wolkenstein; E Sbidian; M Beylot-Barry
Journal:  Br J Dermatol       Date:  2020-08-09       Impact factor: 11.113

8.  Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients.

Authors:  V Piccolo; I Neri; C Filippeschi; T Oranges; G Argenziano; V C Battarra; S Berti; F Manunza; A B Fortina; V Di Lernia; V Boccaletti; G De Bernardis; B Brunetti; C Mazzatenta; A Bassi
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-05-15       Impact factor: 6.166

9.  Relapse of chilblain-like lesions during the second wave of the COVID-19 pandemic: a cohort follow-up.

Authors:  T Hubiche; F Le Duff; E Fontas; J Rapp; C Chiaverini; T Passeron
Journal:  Br J Dermatol       Date:  2021-07-05       Impact factor: 11.113

10.  Impaired type I interferon response in SARS-CoV-2 infection: looking through the cutaneous window.

Authors:  D Bessis
Journal:  Br J Dermatol       Date:  2020-11-29       Impact factor: 11.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.